This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic urothelial carcinoma session and a presentation by Dr.

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...

Interdisciplinary Genitourinary Cancer Forum featured a metastatic castration resistant prostate cancer (mCRCP) session and a ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

Pre-therapeutic PSMA PET/CT information can be used to predict 177 Lu-PSMA-617 therapy response patterns and outcomes, with various quantitative and visual methods proposed. This study, presented at ...

Dr. Kevin Leung presented an artificial intelligence-based risk score for the prognostic evaluation of prostate cancer patients using PSMA PET/CT imaging. Dr. Leung argued that improved survival ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...